News from takeda pharmaceutical company limited A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 10, 2015, 18:36 ET

FDA Accepts a Supplemental New Drug Application for Review of Brintellix® (vortioxetine) Clinical Trial Data That Assessed Cognitive Function in Patients with Major Depressive Disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has...

Jul 30, 2015, 10:21 ET

Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the study to fulfill the post-marketing commitment and...

Jul 30, 2015, 02:00 ET

Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1%

Guidance for FY2015 confirmed, including Core Earnings and Core EPS   Highlights of Q1 results ...

Jul 27, 2015, 06:00 ET

DNDi and Takeda Collaborate for the Lead Optimization for Aminopyrazole Series for Visceral Leishmaniasis

Drugs for Neglected Diseases initiative (Headquarters: Geneva, Switzerland; Executive Director: Bernard Pécoul, Doctor; "DNDi") and Takeda...

Jun 05, 2015, 17:15 ET

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Takeda Pharmaceutical Company Limited, ("Takeda") today announced additional post-hoc analyses from the global EXAMINE (EXamination of...

May 15, 2015, 02:26 ET

Takeda Reports Top Line Results in Line With Guidance, With Underlying Growth of +2.8% EPS Affected by One-time Charges in FY2014 Back to Profitable Growth from FY2015 Onward

Operational guidance met  - Underlying revenue +2.8% year-over-year, in line with guidance (reported revenue growing +5.1% to 1,777.8...

Apr 16, 2015, 23:11 ET
Researchers at Takeda and CiRA at Kyoto University, Japan, will collaborate on developing game-changing therapeutics by applying iPS cell and related technologies to pharmaceutical R&D activities, such as drug discovery, cell therapy and drug safety. CiRA Director Shinya Yamanaka, a Nobel laureate for his work on iPS cells, will direct the program, while Takeda provides long-term funding, recommendations on research management, and facilities at Shonan Research Center.

CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research

 Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that...

Apr 14, 2015, 19:00 ET

FDA Advisory Committee Reviews Takeda's Alogliptin EXAMINE Cardiovascular Safety Outcomes Trial

Takeda Pharmaceuticals U.S.A. Inc. and Takeda Pharmaceutical Company Limited, ("Takeda") today announced that members of the Endocrinologic and...

Apr 13, 2015, 08:40 ET

Takeda Announces Appointment of New President of U.S. Business Unit

 Takeda Pharmaceutical Company Limited ("Takeda"), and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA")...

Mar 09, 2015, 20:20 ET

Takeda Announces Publication in The Lancet of a Post Hoc Analysis of Data from the EXAMINE Cardiovascular Safety Outcomes Trial

Takeda Pharmaceutical Company Limited (Takeda) announced that a post hoc analysis of data from the global EXAMINE (EXamination of CArdiovascular...

Mar 09, 2015, 13:15 ET

Takeda Hosts Investor Briefing on its Global Leadership in Gastroenterology

 Takeda Pharmaceutical Company Limited ("Takeda") today held a briefing for investors and analysts in New York, discussing the company's...

Jan 12, 2015, 08:00 ET

Prasco and Takeda Enter into Agreement to Market Authorized Generic of Colcrys® (colchicine, USP) in the United States

CINCINNATI and DEERFIELD, Ill., Jan. 12, 2015 /PRNewswire/ -- Prasco Laboratories ("Prasco"), Takeda Pharmaceutical Company Limited...

Oct 27, 2014, 11:00 ET

Trate los síntomas del reflujo gracias a la Food4GERD App

La enfermedad del reflujo gastroesofágico (GERD), a menudo conocida como ardor de estómago, es un problema importante para muchas...

Oct 20, 2014, 08:00 ET

Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults

 Takeda Pharmaceutical Company Limited ("Takeda"), its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen®...

Aug 28, 2014, 12:09 ET

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from...

Jul 10, 2014, 09:00 ET

Takeda and Zinfandel Pharmaceuticals to Present Data at Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches to Alzheimer's Disease Research and Development

 Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during...

Jun 17, 2014, 09:00 ET

Results of a New Study of Brintellix® (vortioxetine) vs. Escitalopram on Sexual Functioning in Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction

Takeda Pharmaceuticals Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will present results about sexual...

Jun 16, 2014, 10:00 ET

ENTYVIO™ (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the...

Jun 16, 2014, 06:30 ET

New CONNECT Study Presents data on Measures of Cognitive Performance in Adult Patients Treated with Brintellix® (vortioxetine) for Major Depressive Disorder

 Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated...

May 20, 2014, 18:14 ET

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the...